市場調查報告書

皮膚癌:機會評估,流行病學研究,市場動態,及開發平台分析(2020年下半年)

Skin Cancers - Opportunity Assessments, Epidemiology Studies, Market Dynamics, and Pipeline Analytics H2 2020

出版商 GervanoRA Data Services LLP 商品編碼 968652
出版日期 內容資訊 英文 343 Pages
訂單完成後即時交付
價格
皮膚癌:機會評估,流行病學研究,市場動態,及開發平台分析(2020年下半年) Skin Cancers - Opportunity Assessments, Epidemiology Studies, Market Dynamics, and Pipeline Analytics H2 2020
出版日期: 2020年11月03日內容資訊: 英文 343 Pages
簡介

本報告提供皮膚癌的相關調查,皮膚癌及市場概要,市場機會,成長及阻礙因素,進行中的研究開發階段和各市場區隔的開發平台分析,競爭情形,主要企業的詳細的洞察及新興企業的簡介等資訊。

目錄

第1章 簡介

第2章 摘要整理

  • 報告概要
  • 皮膚癌的競爭空間主要的活動
  • 主要調查結果的報告
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 競爭情形的市場動態
    • 新興療法的未滿足需求與市場的需求
    • 給藥途徑的未滿足需求與市場的需求
    • 各地區的未滿足需求與市場的需求

第3章 開發平台分析預測

  • 開發平台分析比較概述
    • 各開發階段
    • 各地區
    • 各給藥途徑
    • 各分子類型
    • 各醫藥品分類
    • 各類型企業
    • 各分子標的

第4章 皮膚癌概要

第5章 皮膚癌的市場動態

第6章 皮膚癌開發平台的專利分析

第7章 皮膚癌的開發平台分析

  • 各開發階段的開發平台分析
    • 前登記
    • 階段III
    • 階段II
    • 階段I/II
    • 階段I
    • 前臨床
    • 初期R&D
    • 非活動和結束的開發平台
  • 各地區
  • 各給藥途徑
    • 各非口服
    • 各口服及局部
  • 各醫藥品分類
  • 各作用機制
  • 各分子類型
  • 各目標受體
  • 各皮膚癌類型
  • 各類型企業

第8章 開發平台藥物的說明與開發里程碑

第9章 臨床試驗概要

第10章 開發平台估計核准計劃

第11章 各競爭基準機會評估

第12章 現在及未來的競爭情形

  • 新興企業的簡介
目錄

GervanoRA's pipeline analysis and opportunity assessment report "Skin Cancers - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2020" analyzed and assessed Skin Cancer pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Skin Cancers drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Skin Cancers area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Skin Cancers drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

Our comprehensive analysis on the Skin Cancers drug pipeline identified 681 drug candidates undergoing different stages of development- from Early R&D stage to Phase 3 stage and Pre-Registration. Among these, a total of 388 drug candidates are in clinical stages of development and 195 molecules are in non-clinical stage of development. The drug pipeline consists of three (03) pipeline molecules in pre-registration, 36 pipeline molecules are in late clinical stage of development (Phase 3), and a total of 163 pipeline molecules in early clinical stage of development (Phase 1). The report also aims to provide analytics and deep insights on the expected market share of the key Phase 3 and Phase 2 pipeline drugs for a better understanding of the Skin Cancers market in the coming years and know the competition which is paramount for any new entrant.

The report has covered more than 575 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)
  • Epidemiological Studies
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 2 and Phase 3) Pipeline Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Plotting of the Anticipated Market Share for the New Entrants (Phase 3 and Phase 2 Drugs)
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE SKIN CANCER COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES
  • 2.4. MARKET DYNAMICS OF SKIN CANCERS COMPETITIVE LANDSCAPE
    • 2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
    • 2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION
    • 2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

  • 3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
    • 3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
    • 3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
    • 3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION
    • 3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
    • 3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS
    • 3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE
    • 3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET

CHAPTER 04: SKIN CANCERS OVERVIEW

CHAPTER 05: MARKET DYNAMICS OF SKIN CANCERS COMPETITIVE SPACE

CHAPTER 6: PATENT ANALYTICS OF SKIN CANCERS PIPELINE DRUGS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF SKIN CANCERS

  • 7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 7.1.1. PRE-REGISTRATION PIPELINE DRUGS
    • 7.1.2. PHASE III PIPELINE DRUGS
    • 7.1.3. PHASE II PIPELINE DRUGS
    • 7.1.4. PHASE I/II PIPELINE DRUGS
    • 7.1.5. PHASE I PIPELINE DRUGS
    • 7.1.6. PRE-CLINICAL PIPELINE DRUGS
    • 7.1.7. EARLY R&D PIPELINE DRUGS
    • 7.1.8. INACTIVE AND TERMINATED PIPELINE DRUGS
  • 7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 7.3.1. PIPELINE ANALYTICS BY PARENTERALS AS ROUTE OF ADMINISTRATION
    • 7.3.2. PIPELINE ANALYTICS BY ORAL AND TOPICAL ROUTE OF ADMINISTRATIONS
  • 7.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
  • 7.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
  • 7.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 7.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
  • 7.8. PIPELINE DRUGS ANALYTICS BY SKIN CANCER TYPE
  • 7.9. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 09: CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF PIPELINE DRUGS

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

12.1: EMERGING COMPANIES

    • 12.1.1 EMERGING COMPANY PROFILES